Intelligent Bio Solutions announced significantly improved accuracy (98.2%) and sensitivity (94.6%) for its fingerprint drug screening system in detecting codeine, leading to an accelerated FDA 510(k) submission timeline to September 2026. This positive development de-risks the company's path to market entry in the U.S. and could be a significant catalyst for future growth.
Intelligent Bio Solutions reported highly positive results from its latest Method Comparison Study for its Intelligent Fingerprinting Drug Screening System, demonstrating 98.2% accuracy and 94.6% sensitivity for codeine detection, a notable improvement over previous studies. This strong performance, particularly the 100% specificity, is crucial for FDA approval and workplace drug testing applications. Consequently, the company has accelerated its 510(k) submission to September 2026, signaling confidence in its data. This development significantly de-risks the company's entry into the lucrative U.S. market, presenting a substantial long-term opportunity for INBS as it moves closer to commercialization.